In the past week, GILD stock has gone down by -3.91%, with a monthly decline of -2.68% and a quarterly surge of 15.39%. The volatility ratio for the week is 2.62%, and the volatility levels for the last 30 days are 2.39% for Gilead Sciences, Inc. The simple moving average for the past 20 days is -4.92% for GILD’s stock, with a 23.28% simple moving average for the past 200 days.
Is It Worth Investing in Gilead Sciences, Inc (NASDAQ: GILD) Right Now?
The price-to-earnings ratio for Gilead Sciences, Inc (NASDAQ: GILD) is above average at 291.69x. The 36-month beta value for GILD is also noteworthy at 0.37. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 5 rating it as “overweight,” 11 rating it as “hold,” and 0 rating it as “sell.”
The public float for GILD is 1.24B, and at present, short sellers hold a 1.82% of that float. The average trading volume of GILD on March 24, 2025 was 7.90M shares.
GILD) stock’s latest price update
Gilead Sciences, Inc (NASDAQ: GILD)’s stock price has gone rise by 1.14 in comparison to its previous close of 105.87, however, the company has experienced a -3.91% decrease in its stock price over the last five trading days. seekingalpha.com reported 2025-03-23 that Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI’s conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Oppenheimer repeating the rating for GILD by listing it as a “Outperform.” The predicted price for GILD in the upcoming period, according to Oppenheimer is $132 based on the research report published on March 04, 2025 of the current year 2025.
Deutsche Bank, on the other hand, stated in their research note that they expect to see GILD reach a price target of $120. The rating they have provided for GILD stocks is “Buy” according to the report published on February 18th, 2025.
DZ Bank gave a rating of “Buy” to GILD, setting the target price at $108 in the report published on February 13th of the current year.
GILD Trading at 3.62% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.74% of loss for the given period.
Volatility was left at 2.39%, however, over the last 30 days, the volatility rate increased by 2.62%, as shares sank -2.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.15% upper at present.
During the last 5 trading sessions, GILD fell by -3.91%, which changed the moving average for the period of 200-days by +68.82% in comparison to the 20-day moving average, which settled at $112.62. In addition, Gilead Sciences, Inc saw 15.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from Dickinson Andrew D, who sale 2,500 shares at the price of $110.53 back on Mar 17 ’25. After this action, Dickinson Andrew D now owns 170,674 shares of Gilead Sciences, Inc, valued at $276,325 using the latest closing price.
ANDREW DICKINSON, the Officer of Gilead Sciences, Inc, proposed sale 2,500 shares at $110.53 during a trade that took place back on Mar 17 ’25, which means that ANDREW DICKINSON is holding shares at $276,325 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc stands at 0.02. The total capital return value is set at 0.18. Equity return is now at value 2.28, with 0.79 for asset returns.
Based on Gilead Sciences, Inc (GILD), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at 0.41. The debt to equity ratio resting at 1.38. The interest coverage ratio of the stock is 8.53.
Currently, EBITDA for the company is 1.66 billion with net debt to EBITDA at 3.77. When we switch over and look at the enterprise to sales, we see a ratio of 5.22. The receivables turnover for the company is 6.5for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.60.
Conclusion
In summary, Gilead Sciences, Inc (GILD) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
